3925 West Braker Lane
77 articles with Savara
Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer AUSTIN, Texas--( BUSINESS WIRE )-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Company’s Board of Directors has appo
Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT. Interested parties can access a live audio webcast on the Investors page of the Sav
Savara Announces New England Journal of Medicine ( NEJM ) Publication of IMPALA Study Results Inhaled Molgramostim Improved Outcomes that Reflect Physiological, Radiological, Biochemical, and Clinical Manifestations of aPAP AUSTIN, Texas--( BUSINESS WIRE )-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramost
Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex, an inhaled formula
Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Savara to Present at the 40 th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT). Shareholders and other interested parties may access the call by dialing (855) 239-3120 from the U.S.,
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:30 a.m. ET / 7:30 a.m. PT.
Meeting to Be Held on Friday, May 29, 2020 in Virtual-Only Format
Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP
Savara Inc., an orphan lung disease company, announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020.
Management to Host Conference Call / Webcast with Bronchiectasis Expert Dr. James Chalmers.
Savara Inc., an orphan lung disease company, provided an update on the impact COVID-19 has had on two of the Company’s clinical studies in cystic fibrosis.
Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exposure to Molgradex
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Molgradexvis an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, for the treatment of aPAP.
Dr. van Es-Johansson, an expert in orphan drug development, is currently the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the Company's new Chief Medical Officer, an option to purchase 300,000 shares of the Company's common stock with an exercise price of $1.01 per share,
FDA Pulmonary, Allergy, and Rheumatology Division Veteran and Researcher Will Oversee the Company’s Medical and Regulatory Strategy
Savara Inc., an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel.
Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis Program